Visterra Inc is a dynamic biologics research and early-stage clinical development company that specializes in developing groundbreaking therapies for patients with immune-mediated and other hard-to-treat diseases. With a strong focus on innovation, teamwork, and perseverance, Visterra is committed to making a meaningful impact in the medical field. At Visterra, they believe in the power of innovative technologies and approaches.

Their unique approach includes utilizing cutting-edge computational, AI, and experimental research methods, as well as agile preclinical development, reliable manufacturing, and creative trial designs. This allows them to develop novel therapeutics that go above and beyond traditional standards of care. One of their lead programs is Sibeprenlimab (VIS649), an investigational humanized IgG2 monoclonal antibody aimed at treating Immunoglobulin A Nephropathy (IgAN), a chronic and progressive kidney disease.

Driven by a culture marked by curiosity and guided by the scientific method, Visterra's team is deeply dedicated to extending and improving the lives of individuals affected by immune-mediated diseases. Join their collaborative, high-performing, agile team and be empowered to make a real difference in the world of biologics